|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's Range||N/A - N/A|
|52 Week Range||undefined - undefined|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
In July 2017, the FDA accepted Bristol-Myers Squibb’s supplemental New Drug Application (or sNDA) for expanding the indication of Sprycel.
Incyte (INCY) reported revenues of $384.1 million in its 1Q17 results, which translates to 45.7% revenue growth in 1Q17 as compared to $263.5 million in 1Q16.
Incyte’s (INCY) Jakafi is distributed in the United States through a network of specialty pharmacy providers and wholesalers for direct delivery.
ARIAD Pharmaceuticals, Inc. (ARIA) announced the submission of a Marketing Authorisation Application (MAA) for its experimental ALK inhibitor, brigatinib, with the European Medicines Agency (EMA).
ARIAD Pharmaceuticals, Inc. today announced the submission of a Marketing Authorization Application for its investigational oral anaplastic lymphoma kinase inhibitor, brigatinib, to the European Medicines Agency .
Upcoming AWS Coverage on ARIAD Pharmaceuticals LONDON, UK / ACCESSWIRE / February 1, 2017 / Active Wall St. blog coverage looks at the headline from Exelixis, Inc. (NASDAQ: EXEL ) as the Company and Japan ...
Ariad had to put off requests from a potential suitor in order to lock in an increased buyout offer from Takeda Pharmaceuticals.
Biotechs have a lot riding on drug data in 2017 with nearly two dozen firms reporting data in four key segments.
High-priced medicine sold by Eli Lilly & Co., Pfizer, Seattle Genetics, Ariad Pharmaceuticals, and Novelion Therapeutics could put those companies in Donald Trump's disfavor.
NEW YORK, Jan. 18, 2017 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Ariad Pharmaceuticals, Inc. (NASDAQ: ARIA) ("ARIA" or the "Company") in connection with the proposed acquisition of the Company by Takeda Pharmaceutical Company Limited ("Takeda"). On January 9, 2017, Takeda announced a definitive agreement to acquire all outstanding shares of ARIA in a transaction valued at approximately $5.2 billion. Under the terms of the agreement, the Company's shareholders will receive $24.00 in cash for each ARIA share they own.
Jazz Pharmaceuticals Public Limited Company (JAZZ) announced the initiation of a phase III clinical study on its marketed drug, Defitelio (defibrotide), for the potential prevention of veno-occlusive disease.
Becton, Dickinson and Company (BDX), popularly known as BD, recently announced that it has made its Precise whole transcriptome analysis kits commercial available.
NEW YORK, Jan. 13, 2017 /PRNewswire/ -- Nadeem Faruqi, founding partner at Faruqi & Faruqi, LLP , a leading national securities firm headquartered in New York City, is investigating the Board of Directors ...